Header

UZH-Logo

Maintenance Infos

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)


Peters, Solange; Dafni, Urania; Boyer, Michael; De Ruysscher, Dirk; Faivre-Finn, Corinne; Felip, Enriqueta; Garrido, Pilar; Girard, Nicolas; Guckenberger, Matthias; Haanen, John; Le Pechoux, Cecile; Mornex, Francoise; Ozsahin, Mahmut; Paz-Ares, Luis; Planchard, David; Raben, David; Ramalingam, Suresh; Reck, Martin; Smit, Egbert; Stahel, Rolf; Stenzinger, Albrecht; Swanton, Charlie; Vallone, Stefania; Garassino, Marina (2019). Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Annals of Oncology, 30(2):161-165.

Statistics

Citations

Dimensions.ai Metrics
3 citations in Web of Science®
2 citations in Scopus®
Google Scholar™

Altmetrics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Radiation Oncology
04 Faculty of Medicine > University Hospital Zurich > Clinic for Oncology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:1 February 2019
Deposited On:12 Feb 2019 15:37
Last Modified:23 Feb 2019 02:07
Publisher:Oxford University Press
ISSN:0923-7534
OA Status:Closed
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1093/annonc/mdy553
PubMed ID:30624547

Download

Full text not available from this repository.
View at publisher

Get full-text in a library